Literature DB >> 28539135

Association between advanced glycation end-products and functional performance in Alzheimer's disease and mixed dementia.

Hans Drenth1, Sytse U Zuidema2, Wim P Krijnen1, Ivan Bautmans3, Cees van der Schans1, Hans Hobbelen1.   

Abstract

BACKGROUND: People with Alzheimer's disease (AD) experience, in addition to the progressive loss of cognitive functions, a decline in functional performance such as mobility impairment and disability in activities of daily living (ADL). Functional decline in dementia is mainly linked to the progressive brain pathology. Peripheral biomechanical changes by advanced glycation end-products (AGEs) have been suggested but have yet to be thoroughly studied.
METHODS: A multi-center, longitudinal, one-year follow-up cohort study was conducted in 144 people with early stage AD or mixed Alzheimer's/Vascular dementia. Linear mixed model analyses was used to study associations between AGE-levels (AGE reader) and mobility (Timed Up and Go), and ADL (Groningen Activity Restriction Scale and Barthel index), respectively.
RESULTS: A significant association between AGE levels and mobility (β = 3.57, 95%CI: 1.43-5.73) was revealed; however, no significant association between AGE levels and ADL was found. Over a one-year time span, mean AGE levels significantly increased, and mobility and ADL performance decreased. Change in AGE levels was not significantly correlated with change in mobility.
CONCLUSIONS: This study indicates that high AGE levels could be a contributing factor to impaired mobility but lacks evidence for an association with ADL decline in people with early stage AD or mixed dementia. Future research is necessary on the reduction of functional decline in dementia regarding the effectiveness of interventions such as physical activity programs and dietary advice possibly in combination with pharmacologic strategies targeting AGE accumulation.

Entities:  

Keywords:  Alzheimer's disease; activities of daily living; advanced glycation end-products; biomarker; dementia; functional mobility

Mesh:

Substances:

Year:  2017        PMID: 28539135     DOI: 10.1017/S1041610217000886

Source DB:  PubMed          Journal:  Int Psychogeriatr        ISSN: 1041-6102            Impact factor:   3.878


  4 in total

Review 1.  The Effects of Dietary Advanced Glycation End-Products on Neurocognitive and Mental Disorders.

Authors:  Nathan M D'Cunha; Domenico Sergi; Melissa M Lane; Nenad Naumovski; Elizabeth Gamage; Anushri Rajendran; Matina Kouvari; Sarah Gauci; Thusharika Dissanayka; Wolfgang Marx; Nikolaj Travica
Journal:  Nutrients       Date:  2022-06-10       Impact factor: 6.706

2.  Alzheimer's disease: a step closer to understanding type 3 diabetes in African Americans.

Authors:  Sherry A Ferguson; John J Panos; Daniel Sloper; Vijayalakshmi Varma; Sumit Sarkar
Journal:  Metab Brain Dis       Date:  2021-05-22       Impact factor: 3.584

3.  Diphlorethohydroxycarmalol Attenuates Methylglyoxal-Induced Oxidative Stress and Advanced Glycation End Product Formation in Human Kidney Cells.

Authors:  Seon-Heui Cha; Yongha Hwang; Soo-Jin Heo; Hee-Sook Jun
Journal:  Oxid Med Cell Longev       Date:  2018-04-22       Impact factor: 6.543

4.  Glycation of macrophages induces expression of pro-inflammatory cytokines and reduces phagocytic efficiency.

Authors:  Veronika Bezold; Philip Rosenstock; Jonas Scheffler; Henriette Geyer; Rüdiger Horstkorte; Kaya Bork
Journal:  Aging (Albany NY)       Date:  2019-07-29       Impact factor: 5.682

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.